199 related articles for article (PubMed ID: 16221056)
1. Postchemotherapy residual masses in advanced seminoma: current management and outcomes.
Quek ML; Simma-Chiang V; Stein JP; Pinski J; Quinn DI; Skinner DG
Expert Rev Anticancer Ther; 2005 Oct; 5(5):869-74. PubMed ID: 16221056
[TBL] [Abstract][Full Text] [Related]
2. Clinical parameters that predict histology of postchemotherapy retroperitoneal lymph node mass in testicular cancer.
Onozawa M; Kawai K; Yamamoto T; Hinotsu S; Tsukamoto S; Hattori K; Miyanaga N; Shimazui T; Akaza H
Int J Urol; 2004 Jul; 11(7):535-41. PubMed ID: 15242364
[TBL] [Abstract][Full Text] [Related]
3. [Management of advanced seminoma: retrospective study of 96 patients].
Bompas E; Fléchon A; Biron P; Droz JP
Bull Cancer; 2002 Oct; 89(10):877-85. PubMed ID: 12441279
[TBL] [Abstract][Full Text] [Related]
4. Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis.
Heidenreich A; Thüer D; Polyakov S
Eur Urol; 2008 Feb; 53(2):260-72. PubMed ID: 18045770
[TBL] [Abstract][Full Text] [Related]
5. Early stage and advanced seminoma: role of radiation therapy, surgery, and chemotherapy.
Gospodarwicz MK; Sturgeon JF; Jewett MA
Semin Oncol; 1998 Apr; 25(2):160-73. PubMed ID: 9562449
[TBL] [Abstract][Full Text] [Related]
6. Myths and facts on adjuvant carboplatin for stage I seminoma.
Aparicio J; Germà JR
J Clin Oncol; 2006 Jul; 24(21):e40. PubMed ID: 16849740
[No Abstract] [Full Text] [Related]
7. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma.
Ganjoo KN; Chan RJ; Sharma M; Einhorn LH
J Clin Oncol; 1999 Nov; 17(11):3457-60. PubMed ID: 10550142
[TBL] [Abstract][Full Text] [Related]
8. [Observation policy for residual masses after chemotherapy for gonadal and extra-gonadal germ cell tumors].
Takizawa A; Miura T; Fujinami K; Osada Y
Hinyokika Kiyo; 2005 Apr; 51(4):247-51. PubMed ID: 15912783
[TBL] [Abstract][Full Text] [Related]
9. Editorial comment on: postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumors of the testis.
Jacqmin D
Eur Urol; 2008 Feb; 53(2):272-3. PubMed ID: 18045771
[No Abstract] [Full Text] [Related]
10. Editorial comment on: postchemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer tumors of the testis.
Culine S
Eur Urol; 2008 Feb; 53(2):273-4. PubMed ID: 18045772
[No Abstract] [Full Text] [Related]
11. [Late relapse of stage I testicular seminoma after 11 years: successful treatment with chemotherapy alone].
Detti B; Cipressi S; Di Cataldo V; Biti G
Actas Urol Esp; 2010 Jan; 34(1):118-9. PubMed ID: 20223144
[No Abstract] [Full Text] [Related]
12. Management of post-chemotherapy residual masses in advanced seminoma.
Flechon A; Bompas E; Biron P; Droz JP
J Urol; 2002 Nov; 168(5):1975-9. PubMed ID: 12394688
[TBL] [Abstract][Full Text] [Related]
13. [Value of limited dissection of residual retroperitoneal masses after chemotherapy for malignant non-seminoma tumors of the testis. Apropos of 74 cases].
Houdelette P; Houlgatte A; Berlizot P
Chirurgie; 1997; 122(7):404-7. PubMed ID: 9588059
[TBL] [Abstract][Full Text] [Related]
14. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group.
Winter C; Pfister D; Busch J; Bingöl C; Ranft U; Schrader M; Dieckmann KP; Heidenreich A; Albers P
Eur Urol; 2012 Feb; 61(2):403-9. PubMed ID: 22078334
[TBL] [Abstract][Full Text] [Related]
15. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study.
Aparicio J; Germà JR; García del Muro X; Maroto P; Arranz JA; Sáenz A; Barnadas A; Dorca J; Gumà J; Olmos D; Bastús R; Carles J; Almenar D; Sánchez M; Paz-Ares L; Satrústegui JJ; Mellado B; Balil A; López-Brea M; Sánchez A;
J Clin Oncol; 2005 Dec; 23(34):8717-23. PubMed ID: 16260698
[TBL] [Abstract][Full Text] [Related]
16. [Management of patients with seminoma, residual after induction chemotherapy, and disseminated in the retroperitoneal space].
Bulanov AA; Tiuliandin SA; Nasyrova RIu; Timov DA; Mitin AV; Sholokhov VN; Garin AM
Vopr Onkol; 1999; 45(4):451-4. PubMed ID: 10532112
[No Abstract] [Full Text] [Related]
17. [Retroperitoneal residual tumor resection after chemotherapy of malignant testicular cancers].
Albers P
Aktuelle Urol; 2012 May; 43(3):197-206. PubMed ID: 22639031
[No Abstract] [Full Text] [Related]
18. Resection of small, residual retroperitoneal masses after chemotherapy for nonseminomatous testicular cancer: a decision analysis.
Steyerberg EW; Marshall PB; Keizer HJ; Habbema JD
Cancer; 1999 Mar; 85(6):1331-41. PubMed ID: 10189139
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study.
Garcia-del-Muro X; Maroto P; Gumà J; Sastre J; López Brea M; Arranz JA; Lainez N; Soto de Prado D; Aparicio J; Piulats JM; Pérez X; Germá-Lluch JR
J Clin Oncol; 2008 Nov; 26(33):5416-21. PubMed ID: 18936476
[TBL] [Abstract][Full Text] [Related]
20. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.
Hinz S; Schrader M; Kempkensteffen C; Bares R; Brenner W; Krege S; Franzius C; Kliesch S; Heicappel R; Miller K; de Wit M
J Urol; 2008 Mar; 179(3):936-40; discussion 940. PubMed ID: 18207171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
